1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

New Protocol: Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma
Study:
  • Open-label, single-center, phase II study
  • Previously untreated non-GCB DLBCL
  • 60 patients
  • Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RLI) after two cycles, 6 cycles RLI + Standart CT
Efficacy:
  • ORR after two cycles of RLI: 86.2%
  • CR at end of RLI-chemo: 94.5%
  • 2-year-PFS and -OS: 91.3% and 96.6%
Safety:
  • Any grade AEs: Nausea (85%), peripheral sensory neuropathy (83%), diarrhea (78%), mucositis (75%)
  • Grade ≥3 AEs neutropenia 53%, thrombocytopenia 47%, anemia 38%

J Clin Oncol. 2022 Aug 11.

Westin J, Davis RE, Feng L, et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

https://doi.org/10.1200/jco.22.00597

Reviewed by Hasan Çağrı Yıldırım, MD on Sep 27, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More